首页> 外国专利> Humanized type ii anti-cd20 antigen binding molecules and use thereof for the manufacture of a medicament to treat b-cell proliferative disorders or autoimmune diseases

Humanized type ii anti-cd20 antigen binding molecules and use thereof for the manufacture of a medicament to treat b-cell proliferative disorders or autoimmune diseases

机译:人源化的II型抗CD20抗原结合分子及其在制备治疗b细胞增生性疾病或自身免疫性疾病的药物中的用途

摘要

The present invention relates to antigen binding molecules (ABMs). In particular embodiments, the present invention relates to recombinant monoclonal antibodies, including chimeric, primatized or humanized antibodies specific for human CD20. In addition, the present invention relates to nucleic acid molecules encoding such ABMs, and vectors and host cells comprising such nucleic acid molecules. The invention further relates to methods for producing the ABMs of the invention, and to methods of using these ABMs in treatment of disease. In addition, the present invention relates to ABMs with modified glycosylation having improved therapeutic properties, including antibodies with increased Fc receptor binding and increased effector function.
机译:本发明涉及抗原结合分子(ABM)。在特定的实施方案中,本发明涉及重组单克隆抗体,包括对人CD20特异的嵌合,灵长类或人源化抗体。另外,本发明涉及编码此类ABM的核酸分子,以及包含此类核酸分子的载体和宿主细胞。本发明进一步涉及产生本发明的ABM的方法,以及使用这些ABM治疗疾病的方法。另外,本发明涉及具有改善的治疗特性的具有修饰的糖基化的ABM,包括具有增加的Fc受体结合和增加的效应子功能的抗体。

著录项

  • 公开/公告号IL175367A

    专利类型

  • 公开/公告日2014-11-30

    原文格式PDF

  • 申请/专利权人 ROCHE GLYCART AG;

    申请/专利号IL20060175367

  • 发明设计人

    申请日2006-05-01

  • 分类号A61K;A61K39/395;C07H21/04;C07K;C07K16/28;C07K16/40;C12N;C12N9/10;C12P21/04;

  • 国家 IL

  • 入库时间 2022-08-21 15:15:21

相似文献

  • 专利
  • 外文文献
  • 中文文献
获取专利

客服邮箱:kefu@zhangqiaokeyan.com

京公网安备:11010802029741号 ICP备案号:京ICP备15016152号-6 六维联合信息科技 (北京) 有限公司©版权所有
  • 客服微信

  • 服务号